Unmet Needs in the Care of Patients with Duchenne Muscular Dystrophy in Brazil
Authors:
- Alexandra Prufer de Queiroz Campos AraujoAAAlexandra Prufer de Queiroz Campos Araujo
- Andre Vinícius Soares BarbosaABAndre Vinícius Soares Barbosa
- Michele Michelin BeckerMBMichele Michelin Becker
- Andressa Araujo BragaABAndressa Araujo Braga
- Marcela Câmara Machado CostaMCMarcela Câmara Machado Costa
- Alulin Tácio Quadros Santos Monteiro FonsecaAFAlulin Tácio Quadros Santos Monteiro Fonseca
- Marcondes Cavalcante França JuniorMJMarcondes Cavalcante França Junior
- Juliana Gurgel GiannettiJGJuliana Gurgel Giannetti
- Vanessa Van Der LindenVLVanessa Van Der Linden
- Carlos Alberto da Silva MaglianoCMCarlos Alberto da Silva Magliano
- André Luiz Santos PessoaAPAndré Luiz Santos Pessoa
- Edmar ZanoteliEZEdmar Zanoteli
Open Access
- 27 February 2026
- journal article
- research article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (02) , 001-010
Abstract
Duchenne muscular dystrophy is a rare, progressive neuromuscular disorder primarily affecting boys, and it follows a predictable course. Early intervention is essential for effective management, but disparities in the care of patients with rare diseases hinder access to optimal treatment. To identify unmet needs and challenges in the care of patients with Duchenne muscular dystrophy within the Brazilian public health system compared with the private system. A cross-sectional observational study using the Delphi method was conducted with ten neurologists specialized in Duchenne muscular dystrophy. The specialists participated in rounds of surveys to reach consensus on key issues, including diagnosis, treatment, and care. Data was analyzed using descriptive statistics. According to the Delphi panel, the public health system had an average diagnostic delay of 25 months compared with 10 months in the private sector. Although genetic testing is critical, it is not funded by the public health system. Other barriers included delayed corticosteroid treatment, limited access to multidisciplinary care, and insufficient medical devices. Patients in the public health system lost ambulation earlier (11–12 years of age) than those in the private sector (13–14 years of age). Life expectancy was significantly shorter in the public system, averaging 19 to 20 years compared with 26 to 27 years of age in the private sector. There are significant disparities in the care of patients with Duchenne muscular dystrophy within Brazil's public health system, resulting in worse outcomes. Enhancing access to genetic testing and early multidisciplinary care is crucial to improve the quality of life and survival of these patients.Keywords
This publication has 31 references indexed in Scilit:
- Global health for rare diseases through primary careThe Lancet Global Health, 2024
- Racial and income inequalities in access to healthcare in Brazilian citiesJournal of Transport & Health, 2023
- Realising the future: Health challenges and achievements in BrazilSSM - Mental Health, 2023
- Inequalities in unmet need for health care services and medications in Brazil: a decomposition analysisThe Lancet Regional Health - Americas, 2023
- Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta‐analysisMuscle & Nerve, 2022
- Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysisEuropean Journal of Epidemiology, 2020
- Muscular dystrophiesThe Lancet, 2019
- Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespanThe Lancet Neurology, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic managementThe Lancet Neurology, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementThe Lancet Neurology, 2018